Henry Schein (NASDAQ:HSIC) Updates Q4 2024 Earnings Guidance

Henry Schein (NASDAQ:HSIC) issued an update on its fourth quarter 2024 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 1.190-1.190 for the period, compared to the consensus earnings per share estimate of 1.230. The company issued revenue guidance of $3.2 billion-$3.2 billion, compared to the consensus revenue estimate of $3.3 billion. Henry Schein also updated its FY 2024 guidance to 4.740-4.740 EPS.

Henry Schein Stock Up 6.1 %

HSIC traded up $4.62 during mid-day trading on Wednesday, reaching $80.72. 610,562 shares of the stock were exchanged, compared to its average volume of 1,010,598. Henry Schein has a 1 year low of $63.67 and a 1 year high of $82.63. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42. The stock has a market capitalization of $10.06 billion, a PE ratio of 33.26, a price-to-earnings-growth ratio of 2.04 and a beta of 0.89. The company has a 50 day moving average price of $73.07 and a two-hundred day moving average price of $71.21.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, November 5th. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.05. The business had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.24 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The firm’s revenue for the quarter was up .4% compared to the same quarter last year. During the same period in the previous year, the company earned $1.32 earnings per share. As a group, research analysts anticipate that Henry Schein will post 4.78 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently commented on HSIC shares. Evercore ISI increased their price target on Henry Schein from $70.00 to $74.00 and gave the company an “in-line” rating in a research report on Tuesday, October 8th. Bank of America upgraded Henry Schein from an “underperform” rating to a “buy” rating and lifted their target price for the stock from $69.00 to $84.00 in a research note on Monday, January 6th. StockNews.com upgraded shares of Henry Schein from a “sell” rating to a “hold” rating in a report on Thursday, November 7th. Barrington Research reiterated an “outperform” rating and issued a $82.00 target price on shares of Henry Schein in a research note on Wednesday, November 6th. Finally, Jefferies Financial Group raised their price target on shares of Henry Schein from $77.00 to $80.00 and gave the stock a “hold” rating in a research note on Thursday, January 23rd. Seven investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $79.30.

Insider Activity at Henry Schein

In other news, COO Michael S. Ettinger sold 12,240 shares of the company’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $75.00, for a total transaction of $918,000.00. Following the sale, the chief operating officer now directly owns 87,706 shares in the company, valued at $6,577,950. This represents a 12.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 1.14% of the stock is owned by company insiders.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.